CD82 and breast cancer: On the other hand, KAI1/CD82 expression was demonstrated to be consistently downregulated during the progression of human colon cancer, as well as breast cancer (Huang et al, 1998), pancreatic cancer (Sho et al, 1998) and nonsmall cell lung cancer (Adachi et al, 1996).